Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

Toxicology Letters

Volumn 219, Issue 2, 2013, Pages 107-115

  Zhu, Litao ^a   Zhao, Li ^a   Wang, Hu ^a   Wang, Yu ^a   Pan, Di ^a   Yao, Jing ^a   Li, Zhiyu ^a   Wu, Guanzhong ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Chk2; G2 M; MCF7 ADR; Oroxylin A; P gp

Indexed keywords

CHECKPOINT KINASE 2; DOCETAXEL; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OROXYLIN A; PACLITAXEL; PROTEIN P53;

ARTICLE; CELL NUCLEUS; CELL STRAIN MCF 7; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; COLORING AGENTS; DRUG RESISTANCE, MULTIPLE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; FLUORESCENT DYES; G2 PHASE; GENES, P53; HUMANS; NF-KAPPA B; P-GLYCOPROTEIN; PROPIDIUM; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RHODAMINE 123; TETRAZOLIUM SALTS; THIAZOLES;

BACTERIA (MICROORGANISMS); SCUTELLARIA BAICALENSIS;

EID: 84876331167     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.01.019     Document Type: Article

References (48)

1. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochemical Pharmacology 2002, 64:573-582.
2. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97. 10.1038/sj.onc.1206056.
3. Blasina A., de Weyer I.V., Laus M.C., Luyten W.H., Parker A.E., McGowan C.H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Current Biology 1999, 9:1-10.
4. Blum R.H., Carter S.K. Adriamycin. A new anticancer drug with significant clinical activity. Annals of Internal Medicine 1974, 80:249-259.
5. Bram E.E., Stark M., Raz S., Assaraf Y.G. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 2009, 11:1359-1370.
6. Brooks T.A., Minderman H., O'Loughlin K.L., Pera P., Ojima I., Baer M.R., Bernacki R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular Cancer Therapeutics 2003, 2:1195-1205.
7. Buolamwini J.K. Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design 2000, 6:379-392.
8. Calcagno A.M., Kim I.W., Wu C.P., Shukla S., Ambudkar S.V. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Current Drug Delivery 2007, 4:324-333.
9. Chan H.S., Haddad G., Thorner P.S., DeBoer G., Lin Y.P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New England Journal of Medicine 1991, 325:1608-1614. 10.1056/NEJM199112053252304.
10. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., Zhang X., Annan R.S., Lu Q., Faucette L.F., Scott G.F., Li X., Carr S.A., Johnson R.K., Winkler J.D., Zhou B.B. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18:4047-4054. 10.1038/sj.onc.1202925.
11. Chen C.H., deGraffenried L.A. Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status. Phytomedicine 2012, 19:763-767. 10.1016/j.phymed.2012.02.017.
12. Chen Y., Yang L., Lee T.J. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochemical Pharmacology 2000, 59:1445-1457.
13. 4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line. International Journal of Nanomedicine 2012, 7:2843-2852. ijn-7-2843 [pii]. 10.2147/IJN.S32065.
14. Collins K., Jacks T., Pavletich N.P. The cell cycle and cancer. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2776-2778.
15. Deng L., Lin-Lee Y.C., Claret F.X., Kuo M.T. 2-Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. Journal of Biological Chemistry 2001, 276:413-420. 10.1074/jbc.M004551200.
16. Desoize B., Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Critical Reviews in Oncology/Hematology 2000, 36:193-207.
17. Donmez Y., Akhmetova L., Iseri O.D., Kars M.D., Gunduz U. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemotherapy and Pharmacology 2011, 67:823-828. 10.1007/s00280-010-1385-y.
18. Efferth T., Fu Y.J., Zu Y.G., Schwarz G., Konkimalla V.S., Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Current Medicinal Chemistry 2007, 14:2024-2032.
19. Ford J.M., Yang J.M., Hait W.N. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treatment and Research 1996, 87:3-38.
20. Gao Y., Lu N., Ling Y., Chen Y., Wang L., Zhao Q., Qi Q., Liu W., Zhang H., You Q., Guo Q. Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. Journal of Cancer Research and Clinical Oncology 2010, 136:667-675. 10.1007/s00432-009-0705-2.
21. Gogineni V.R., Nalla A.K., Gupta R., Dinh D.H., Klopfenstein J.D., Rao J.S. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Letters 2011, 313:64-75. 10.1016/j.canlet.2011.08.022.
22. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002, 2:48-58. 10.1038/nrc706.
23. Hajduch M., Havlieek L., Vesely J., Novotny R., Mihal V., Strnad M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Advances in Experimental Medicine and Biology 1999, 457:341-353.
24. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000, 287:1824-1827.
25. Holmes J.A., West R.R. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. British Journal of Cancer 1994, 69:382-384.
26. Jowsey P.A., Williams F.M., Blain P.G. DNA damage, signalling and repair after exposure of cells to the sulphur mustard analogue 2-chloroethyl ethyl sulphide. Toxicology 2009, 257:105-112. 10.1016/j.tox.2008.12.001.
27. Lee E., Enomoto R., Koshiba C., Hirano H. Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Annals of the New York Academy of Sciences 2009, 1171:132-136. NYAS4722 [pii]. 10.1111/j.1749-6632.2009.04722.x.
28. Li H.B., Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. Journal of Chromatography A 2005, 1074:107-110.
29. Li X., Sun B., Zhu C.J., Yuan H.Q., Shi Y.Q., Gao J., Li S.J., Lou H.X. Reversal of P-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicology In Vitro 2009, 23:29-36. 10.1016/j.tiv.2008.09.015.
30. Liu W., Mu R., Nie F.F., Yang Y., Wang J., Dai Q.S., Lu N., Qi Q., Rong J.J., Hu R., Wang X.T., You Q.D., Guo Q.L. MAC-related mitochondrial pathway in oroxylin-A-induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Letters 2009, 284:198-207. 10.1016/j.canlet.2009.04.021.
31. Ma Y., Wink M. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine 2008, 15:754-758. 10.1016/j.phymed.2007.11.028.
32. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
33. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Current Medicinal Chemistry 2006, 13:1859-1876.
34. Richie R.C., Swanson J.O. Breast cancer: a review of the literature. Journal of Insurance Medicine 2003, 35:85-101.
35. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897. 10.1038/35009130.
36. Sauerbrey A., Zintl F., Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. British Journal of Cancer 1994, 70:1144-1149.
37. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews 2003, 55:3-29.
38. Schultz L.B., Weber B.L. Recent advances in breast cancer biology. Current Opinion in Oncology 1999, 11:429-434.
39. Stockler M., Wilcken N.R., Ghersi D., Simes R.J. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews 2000, 26:151-168.
40. Sun Y., Lu N., Ling Y., Gao Y., Chen Y., Wang L., Hu R., Qi Q., Liu W., Yang Y., You Q., Guo Q. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. European Journal of Pharmacology 2009, 603:22-28. S0014-2999(08)01218-1 [pii]. 10.1016/j.ejphar.2008.12.008.
41. Tan B., Piwnica-Worms D., Ratner L. Multidrug resistance transporters and modulation. Current Opinion in Oncology 2000, 12:450-458.
42. Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. Journal of the National Cancer Institute 1991, 83:111-116.
43. Wang H.W., Lin C.P., Chiu J.H., Chow K.C., Kuo K.T., Lin C.S., Wang L.S. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. International Journal of Cancer 2007, 120:2019-2027. 10.1002/ijc.22402.
44. Yang H.Y., Zhao L., Yang Z., Zhao Q., Qiang L., Ha J., Li Z.Y., You Q.D., Guo Q.L. Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Molecular Carcinogenesis 2012, 51:185-195. 10.1002/mc.20789.
45. Yang Y., Hu Y., Gu H.Y., Lu N., Liu W., Qi Q., Zhao L., Wang X.T., You Q.D., Guo Q.L. Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. Journal of Pharmacy and Pharmacology 2008, 60:1459-1463. 10.1211/jpp/60.11.0006.
46. Zhao L., Chen Z., Wang J., Yang L., Zhao Q., Qi Q., Mu R., You Q.D., Guo Q.L. Synergistic effect of 5-fluorouracil and the flavonoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemotherapy and Pharmacology 2010, 65:481-489. 10.1007/s00280-009-1053-2.
47. Zheng L.H., Bao Y.L., Wu Y., Yu C.L., Meng X., Li Y.X. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Letters 2008, 272:102-109. 10.1016/j.canlet.2008.06.029.
48. Zhu B., Zhao L., Zhu L., Wang H., Sha Y., Yao J., Li Z., You Q., Guo Q. Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway. Toxicology and Applied Pharmacology 2012, 259:387-394. 10.1016/j.taap.2012.01.019.